Aspen Pharmacare Holdings Limited (LDZA.F)
- Previous Close
10.30 - Open
10.30 - Bid 10.70 x --
- Ask 11.10 x --
- Day's Range
10.30 - 10.30 - 52 Week Range
7.70 - 10.90 - Volume
10 - Avg. Volume
4 - Market Cap (intraday)
4.798B - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
19.26 - EPS (TTM)
0.54 - Earnings Date --
- Forward Dividend & Yield 0.17 (1.65%)
- Ex-Dividend Date Sep 20, 2023
- 1y Target Est
--
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
www.aspenpharma.com8,612
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: LDZA.F
Performance Overview: LDZA.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LDZA.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LDZA.F
Valuation Measures
Market Cap
4.80B
Enterprise Value
6.00B
Trailing P/E
19.40
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.21
Price/Book (mrq)
1.10
Enterprise Value/Revenue
0.14
Enterprise Value/EBITDA
0.74
Financial Highlights
Profitability and Income Statement
Profit Margin
11.40%
Return on Assets (ttm)
4.10%
Return on Equity (ttm)
6.05%
Revenue (ttm)
42.7B
Net Income Avi to Common (ttm)
4.87B
Diluted EPS (ttm)
0.54
Balance Sheet and Cash Flow
Total Cash (mrq)
11.6B
Total Debt/Equity (mrq)
42.19%
Levered Free Cash Flow (ttm)
22.38M
Company Insights: LDZA.F
LDZA.F does not have Company Insights